Praxis Precision Medicines
PRAXNASDAQSmall molecule therapeutics targeting ion channels and neurotransmitter receptors
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-09-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-09-09 · where each field comes from
Key figures from SEC filings
PRAX filings on EDGAR →Cash & investments
$1.37B
at June 30, 2026 (10-Q)
Quarterly operating burn
$81.8M
average per quarter, Jan–Jun 2026
Cash runway
~50 months
$1.37B ÷ $81.8M per quarter
Shares outstanding
27.9M
cover page of the latest filing
Read from PRAX's XBRL financial data; latest filing August 6, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Pre-revenue.
Upcoming catalysts
No upcoming catalyst for Praxis Precision Medicines has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| PRAX-562 | Developmental and epileptic encephalopathies (DEEs), including SCN2A and SCN8A-related epilepsy | Phase 2 | Not disclosed | ▼ |
| PRAX-114 | Major Depressive Disorder (MDD) | Phase 2 | Not disclosed | ▼ |
| PRAX-628 | Focal Onset Seizures | Phase 2 | Not disclosed | ▼ |
What does Praxis Precision Medicines do?
Praxis Precision Medicines is a small biotech company that develops drugs for brain disorders like epilepsy and depression. They focus on finding the right drug for the right patient by targeting specific genetic causes. Their main drug, PRAX-562, is being tested for rare forms of epilepsy that are caused by mutations in sodium channels. If it works, it could be a new treatment for kids who don't respond to current drugs. They also have a drug for major depression that works differently than existing ones, and another for general epilepsy. The company is still in early stages, so they don't have any products on the market yet. They have enough money to run for about a year and a half. For investors, the big question is whether their drugs will show clear benefits in clinical trials. If they do, the stock could go up a lot because there's a huge need for better brain drugs. But if the trials fail, the stock could drop sharply. It's a risky bet, but with multiple chances to succeed, it could pay off.
What to watch
Monitor enrollment and any updates from the Phase 2 trials for PRAX-562, PRAX-628, and PRAX-114.
Watch for presentations at major neurology conferences like AAN, CTAD, or AD/PD where interim data might be presented.
Track the company's cash burn and any announcements of additional financing or partnerships.
Follow regulatory news from the FDA regarding breakthrough therapy designations or orphan drug status for PRAX-562.
Keep an eye on competitor data readouts in similar indications to gauge the competitive landscape.
Investment thesis
High RiskBull case
Praxis Precision Medicines is a leader in developing precision therapies for CNS disorders, targeting specific genetic and biological pathways. The company's lead asset, PRAX-562, has the potential to be a best-in-class treatment for rare epilepsies with high unmet need. Positive phase 2 data could lead to accelerated approval and significant commercial opportunity. Additionally, the pipeline includes PRAX-114 for major depressive disorder, a large market with a high failure rate, but if successful, could be a blockbuster. The company has a strong cash position to fund operations into 2026, and multiple data readouts in the next 18 months provide multiple catalysts. With a seasoned management team and strategic partnerships, Praxis is well-positioned to create substantial shareholder value.
Bear case
Praxis faces significant risks inherent in CNS drug development. The phase 2 trial for PRAX-562 may fail to meet primary endpoints due to high placebo response or insufficient efficacy, leading to a substantial stock decline. The MDD program is highly competitive, with established players like Sage and Axsome, and PRAX-114 may not differentiate enough to gain market share. The company's cash runway is only 18 months, and if trials are delayed or fail, it may need to raise capital at dilutive terms. Additionally, the precision medicine approach requires genetic testing and may limit the addressable patient population, impacting commercial potential. Regulatory hurdles and safety concerns could also derail development. Overall, the risk is high, and investors could lose a significant portion of their investment.
Risk factors
Clinical trial failure in any of the three programs could severely impact the stock.
CNS trials are prone to high placebo response and difficulty in demonstrating statistical significance.
Competition from larger pharmaceutical companies with more resources in MDD and epilepsy.
Dependence on genetic biomarkers may limit patient recruitment and market size.
Potential safety issues with sodium channel blockers, such as dizziness or cognitive impairment.
Need for additional capital if trials are delayed or fail, leading to dilution.
Comparable companies
Sponsored
Get premium PRAX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you